Paclitaxel an active pharmaceutical ingredient along with the substance docetaxel are medically approved as effective treatments for many types of cancers-most notably bile duct cancer.
According to a new finding revealed by American Society of Oncology’s (ASCO) Gastrointestinal Cancer Symposium, if the compound paclitaxel is mixed with albumin — the new compound formed is known as “Nab- paclitaxel” — could be very effective against cancer of the bile duct. Owing to pricing pressures there have been considerable reduction in the price of paclitaxel. This trend, opine market analysts, is likely to boost the growth of global and Chinese paclitaxel industry.
Gerald Prager ,a researcher from the University Department of Internal Medicine, MedUni Vienna adds “The primary objective with an aggressive disease such as bile duct cancer is to control the disease while maintaining or improving the patient's quality of life. Initial data confirms that nab-paclitaxel is likely to have a high degree of biological effectiveness with few side effects”.
Prof Research Reports has added a report entitled “Global and Chinese Paclitaxel Industry, 2009-2019”. The report offers an in-depth analysis of the current and future market dynamics, business strategies and market of the leading clients, constraints and growth opportunities.